Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | CLL news from ASH 2018: ibrutinib strikes again!

Stephan Stilgenbauer • 6 Dec 2018
ASH 2018
Chronic Lymphocytic Leukemia Leukemia Bendamustine Ibrutinib Obinutuzumab Rituximab Venetoclax
ALLIANCE A041202 ECOG-E1912 iLLUMINATE MURANO

Stephan Stilgenbauer, MD, of the University of Ulm, Ulm, Germany, discusses the chronic lymphocytic leukemia (CLL) highlights at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Stephan Stilgenbauer

2:00
Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
Stephan Stilgenbauer • 11 Dec 2023
2:52
Acquired mutations associated with resistance to BTKi in patients with CLL
Stephan Stilgenbauer • 11 Dec 2023
2:51
Genetic markers in patients with early-stage CLL treated with ibrutinib: findings from CLL12
Stephan Stilgenbauer • 11 Dec 2023
2:11
Pre-clinical study on the dual BCL2/BCL-XL inhibitor AZD0466 for the treatment of CLL
Stephan Stilgenbauer • 11 Dec 2023

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals